Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 25 2025
0mins
Should l Buy ?
Source: Yahoo Finance
Financial Performance: Portage Biotech reported a significant reduction in net loss to approximately $6.8 million for the fiscal year ending March 31, 2025, down from $75.4 million the previous year, largely due to decreased operating expenses and non-cash losses related to impairments.
Operational Changes: The company experienced a 75% decrease in research and development costs, primarily due to paused clinical trials and reduced headcount, while general and administrative expenses also saw a decline of about 25%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
